
LITESPARK-022 Trial Design and the DFS Benefit in Adjuvant RCC
Arpita Desai, MD, and Andre Kydd, MD, walk through the LITESPARK-022 enrollment criteria and the 7% disease-free survival benefit at two years.
Desai: Welcome to Between the Lines with CancerNetwork. In the next few minutes, we'll walk through a study that I think has potential to influence clinical practice. We'll talk about what the trial showed and what it means for the patients in front of us. I'm Dr. Arpita Desai, a GU medical oncologist at UCSF. I also lead the kidney cancer program here. With me today is Dr. Kydd.
Kydd: My name is Dr. Andre Kydd, and I'm a GU medical oncologist at Fox Chase Cancer Institute.
Desai: Let's get into it. Dr. Kydd, do you mind walking us through the design of this study?
Kydd: We're talking about the LITESPARK-022 clinical study. It enrolled patients at intermediate-to-high risk for recurrence of their kidney cancer — specifically clear cell kidney cancer — after surgery. The study included patients with specific high-risk histologies, such as sarcomatoid features; pT2, pT3, or pT4 disease; node-positive disease; or M1 patients with resection of both their primary tumor and all sites of metastatic disease, leaving them with no evidence of disease.
Desai: In terms of inclusion criteria, is there a difference between the LITESPARK-022 study and the KEYNOTE-564 study?
Kydd: The overall criteria are very similar. We can go into some of the nuances in terms of the relative proportions of each of those individual subcriteria — patients at very high risk versus M1 with full resection of their primary and all metastatic sites, versus some of the T2 and T3. It's a subtle point but still noteworthy when making cross-trial comparisons.
Desai: I absolutely agree. There's one really important difference as well. The LITESPARK-022 study included patients who could be M1 NED after two years of having a nephrectomy — they slightly increased the window from nephrectomy to study inclusion. But you're right: both studies are very similar in terms of the patients they included.
In terms of the primary endpoint, the study looked at disease-free survival, and what they found was that patients who received the combination of belzutifan and pembrolizumab had a disease-free survival rate of 80.7% at two years, compared to 73.7% in the single-agent arm. How is this meaningful to patients?
Kydd: This is notable because in this setting we're aiming for curative intent, and for some patients this is a really powerful marker. We want to be able to say that these patients are cured, and that's part of the impetus for doing this — and part of the reason for the FDA indication in this setting. It's one of the drivers for advancing this particular regimen. But there are other caveats we'll talk about in just a second.
Desai: You're absolutely right. It's a difference of about 7% at two years, so I think this is really meaningful for patients.
Related to this article







